Company Summary - Renovo Group PLC (LSE:RNVO)
17.00p
0.00p
Pharmaceuticals & BiotechnologyMarket cap: £30.119m
NEW Explore our new and improved report for Renovo Group PLC >>
Gain access to various premium features such as detailed information on financial reports, broker forecasts, directors and shareholders information.
Summary
Biopharmaceutical product company
| Financials - Annual Report (30/09/2011) | ||
|---|---|---|
| Turnover | £m | 15.93 |
| Pre-tax Profit | £m | 0.9 |
| EPS | p | 1.84 |
| DPS | p | - |
| Dividend Yield | % | |
| Director | Board Role |
|---|---|
| Jamie Brooke | Chairman |
| David Blain | Finance Director & Company Sec |
Products Brands & Subsidiaries
Products & Brands
There are no products for this company.
Subsidiaries
Renovo Ltd; Renovo Technologies Ltd
Broker Sentiment (1 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Holding(s) in Company | 09/02/2012 |
| Holding(s) in Company | 01/02/2012 |
| Notice of AGM | 26/01/2012 |